Journal of nuclear medicine : official publication, Society of Nuclear Medicine
-
Comparative Study
64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
Neuroendocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs. We have previously shown the clinical potential of (64)Cu-DOTATATE in a small first-in-human feasibility study. The aim of the present study was, in a larger prospective design, to compare on a head-to-head basis the performance of (64)Cu-DOTATATE and (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implementing (64)Cu-DOTATATE as a routine. ⋯ With these results, we demonstrate that (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnostic performance in NET patients. Therefore, we do not hesitate to recommend implementation of (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC.
-
Simultaneous PET and MR imaging is a promising new technique allowing the fusion of functional (PET) and anatomic/functional (MR) information. In the thoracic-abdominal regions, respiratory motion is a major challenge leading to reduced quantitative and qualitative image accuracy. Correction methodologies include the use of gated frames that lead to low signal-to-noise ratio considering the associated low statistics. More advanced correction approaches, previously developed for PET/CT imaging, consist of either registering all the reconstructed gated frames to the reference frame or incorporating motion parameters into the iterative reconstruction process to produce a single motion-compensated PET image. The goal of this work was to compare these two—previously implemented in PET/CT—correction approaches within the context of PET/MR motion correction for oncology applications using clinical 4-dimensional PET/MR acquisitions. Two different correction approaches were evaluated comparing the incorporation of elastic transformations extracted from 4-dimensional MR imaging datasets during PET list-mode image reconstruction to a postreconstruction image-based approach. ⋯ Our results demonstrate significant respiratory motion compensation using both methods, with superior results from a 4D PET RS approach.
-
This study investigated whether (18)F-FDG PET/CT performed at baseline and during neoadjuvant chemotherapy (NAC) was able to early depict estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer patients with poor clinical outcome. ⋯ Baseline tumor (18)F-FDG uptake and modifications after 2 cycles of NAC are prognostic of outcome in patients with ER+/HER2- breast cancer.
-
Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and treatment of prostate cancer. EuK-Subkff-(68)Ga-DOTAGA ((68)Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Whole-body distribution and radiation dosimetry of this new probe were evaluated. ⋯ (68)Ga-PSMA I&T exhibits a favorable dosimetry, delivering organ doses that are comparable to (kidneys) or lower than those delivered by (18)F-FDG.
-
Respiratory motion during PET acquisition may lead to blurring in resulting images and underestimation of uptake parameters. The advent of integrated PET/MR scanners allows us to exploit the integration of modalities, using high spatial resolution and high-contrast MR images to monitor and correct PET images degraded by motion. We proposed a practical, anatomy-independent MR-based correction strategy for PET data affected by respiratory motion and showed that it can improve image quality both for PET acquired simultaneously to the motion-capturing MR and for PET acquired up to 1 h earlier during a clinical scan. ⋯ We showed that a respiratory signal can be obtained from raw PET data and that the clinical PET image quality can be improved using only a short additional PET/MR acquisition. Our method does not need external respiratory hardware or modification of the normal clinical MR sequences.